Renal Anemia
Pipeline by Development Stage
Drug Modality Breakdown
Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.
Key Trends
- IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
- Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
- 1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders
Career Verdict
Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 65% | Peak | Stable | 8.7yr |
| 2 | PROMACTA (eltrombopag olamine) | Novartis | $558M | 15% | LOE Approaching | Declining | 1.5yr |
| 3 | AURYXIA (ferric citrate) | Ipsen | $183M | 5% | Peak | Stable | 3.9yr |
| 4 | OXBRYTA (voxelotor) | Pfizer | $101M | 3% | Peak | Growing | 11.2yr |
| 5 | DOPTELET (avatrombopag maleate) | Unknown | $96M | 3% | LOE Approaching | Declining | 1.0yr |
Drug Class Breakdown
dominates market, stable
multiple players, patent risk
niche, CKD-focused
sickle cell focused, growing
myeloproliferative neoplasms, early growth
legacy class, biosimilar pressure
biosimilar-saturated, mature
Career Outlook
StableHematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.
Breaking In
Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.
For Experienced Professionals
Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).
In-Demand Skills
Best For
Hiring Landscape
Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (14)
Total enrollment: 6,206 patients across 14 trials
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
Related Jobs in Hematology
Product Specialist - Hematology - Delhi
Medical Science Liaison - Hematology (Florida and Puerto Rico Territory)
Medical Science Liaison - Hematology (Illinois and Michigan Territory)
Associate Vice President of Enterprise Business Development
US Hematology Thought Leader Engagement Lead - Southeast US
Advanced Assay Office/Validation Analyst
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.